Antimicrobial-drug resistance

New England Journal of Medicine

Volumn 335, Issue 19, 1996, Pages 1445-1454

  Gold, Howard S ^a   Moellering Jr , Robert C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; ERYTHROMYCIN; MACROLIDE; QUINOLONE DERIVATIVE; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; DRUG MECHANISM; HUMAN; HUMAN TISSUE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STREPTOCOCCUS INFECTION;

BETA-LACTAM RESISTANCE; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS; GRAM-NEGATIVE BACTERIA; HUMANS; PENICILLIN RESISTANCE; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN;

EID: 0029802138     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199611073351907     Document Type: Review

References (104)

1. Murray BE, Moellering RC Jr. Patterns and mechanisms of antibiotic resistance. Med Clin North Am 1978;62:899-923.
2. Snider DE Jr, Cauthen GM, Farer LS, et al. Drug-resistant tuberculosis. Am Rev Respir Dis 1991;144:732.
3. Jacobs RE Multiple drug resistant tuberculosis. Clin Infect Dis 1994; 19:1-10.
4. Hooper DC, Wolfson JS. Mechanisms of bacterial resistance to quinolones. In: Hooper DC, Wolfson JS, eds. Quinolone antimicrobial agents. 2nd ed. Washington, D.C.: American Society for Microbiology, 1993:97-118.
5. Spratt BG. Hybrid penicillin-binding proteins in penicillin-resistant strains of Neisseria gonorrhoeae. Nature 1988;332:173-6.
6. de la Cruz F, Grinsted J. Genetic and molecular characterization of Tn21, a multiple resistance transposon from R100.1. J Bacteriol 1982;151:222-8.
7. Collis CM, Hall RM. Expression antibiotic resistance genes in the integrated cassettes of integrons. Antimicrob Agents Chemother 1995;39: 155-62.
8. Levesque C, Piche L, Larose C, Roy PH. PCR mapping of integrons reveals several novel combinations of resistance genes. Antimicrob Agents Chemother 1995;39:185-91.
9. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993;37:1563-71.
10. Gardner P, Smith DH, Beer H, Moellering RC Jr. Recovery of resistance (R) factors from a drug-free community. Lancet 1969;2:774-6.
11. Webb V, Davies J. Antibiotic preparations contain DNA: a source of drug resistance genes? Antimicrob Agents Chemother 1993;37:2379-84.
12. Moellering RC Jr. Interaction between antimicrobial consumption and selection of resistant bacterial strains. Scand J Infect Dis Suppl 1990;70: 18-24.
13. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995;273:214-9.
14. New antimicrobial agents approved by the U.S. Food and Drug Administration in 1994 and new indications for previously approved agents. Antimicrob Agents Chemother 1995;39:1010.
15. Lederberg J, Shope RE, Oaks SC Jr, eds. Emerging infections: microbial threats to health in the United States. Washington, D.C.: National Academy Press, 1992.
16. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
17. Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-84.
18. Du Bois SK, Marriott MS, Amyes SGB. TEM- and SHV-derived extended-spectrum β-lactamases: relationship between selection, structure and function. J Antimicrob Chemother 1995;35:7-22.
19. Sanders WE Jr, Sanders CC. Inducible β-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev Infect Dis 1988;10:830-8.
20. Knothe H, Shah P, Krcméry V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11:315-7.
21. Philippon A, Labia R, Jacoby G. Extended-spectrum β-lactamases. Antimicrob Agents Chemother 1989;33:1131-6.
22. Rice LB, Willey SH, Papanicolaou GA, et al. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 1990;34:2193-9.
23. Sirot J, Chanal C, Petit A, Sirot D, Labia R, Gerbaud G. Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated β-lactamases markedly active against third-generation cephalosporins: epidemiologic studies. Rev Infect Dis 1988;10:850-9.
24. Sirot D, De Champs C, Chanal C, et al. Translocation of antibiotic resistance determinants including an extended-spectrum β-lactamase between conjugative plasmids of Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 1991;35:1576-81.
25. Naumovski L, Quinn JP, Miyashiro D, et al. Outbreak of ceftazidime resistance due to a novel extended-spectrum β-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 1992;36:1991-6. [Erratum, Antimicrob Agents Chemother 1993;37:375.]
26. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353-8.
27. Brun-Buisson C, Legrand P, Philippon A, Montravers F, Ansquer M, Duval J. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 1987;2:302-6.
28. Jones RN, Kehrberg EN, Erwin ME, Anderson SC. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances: real or perceived? Diagn Microbiol Infect Dis 1994;19:203-15.
29. Sader HS, Pfaller MA, Jones RN. Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of the intra- and interlaboratory dissemination of extended-spectrum β-lactamase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis 1994;20:203-8.
30. Sougakoff W, Goussard S, Gerbaud G, Couvalin P. Plasmid-mediated resistance to third-gene rat ion cephalosporins caused by point mutations in TEM-type penicillinase genes. Rev Infect Dis 1988;10:879-84.
31. Payne DJ, Cramp R, Winstanley DJ, Knowles DJ. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important β-lactamases. Antimicrob Agents Chemother 1994;38:767-72.
32. Thomson KS, Weber DA, Sanders CC, Sanders WE Jr. β-Lactamase production in members of the family Enterobacteriaceae and resistance to β-lactam-enzyme inhibitor combinations. Antimicrob Agents Chemother 1990;34:622-7.
33. Thomson CJ, Amyes SGB. TRC-1: emergence of a clavulanic acid-resistant TEM β-lactamase in a clinical strain. FEMS Microbiol Lett 1992; 70:113-7.
34. Jarlier V, Nicolas M-H, Fournier G, Philippon A. Extended broad-spectrum ß-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988;10:867-78.
35. Fantin B, Pangon B, Potel G, et al. Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like β-lactamase. Antimicrob Agents Chemother 1990;34:581-6.
36. Caron F, Gutmann L, Bure A, et al. Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad spectrum TEM-3 β-lactamase. Antimicrob Agents Chemother 1990;34:2070-4.
37. Rice LB, Yao JDC, Klimm K, Eliopoulos GM, Moellering RC Jr. Efficacy of different β-lactams against an extended-spectrum β-lactamase-producing Klebsiella pneumoniae strain in the rat infra-abdominal abscess model. Antimicrob Agents Chemother 1991;35:1243-4.
38. Mentec H, Vallois J-M, Bure A, Saleh-Mghir A, Jehl F, Carbon C. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant. Antimicrob Agents Chemother 1992;36: 1883-9.
39. Rice LB, Carias LL, Shlaes DM. In vivo efficacies of β-lactam-β-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 1994;38:2663-4.
40. Pangon B, Bizet C, Buré A, et al. In vivo selection of a cephamycinresistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 β-lactamase. J Infect Dis 1989;159:1005-6.
41. Bryce EA, Smith JA. Focused microbiological surveillance and gram-negative beta-lactamase-mediated resistance in an intensive care unit. Infect Control Hosp Epidemiol 1995;16:331-4.
42. Pallares R, Liǹares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474-80.
43. Gehanno P, Lenoir G, Berche P. In vivo correlates for Streptococcus pneumoniae penicillin resistance in acute otitis media. Antimicrob Agents Chemother 1995;39:271-2.
44. Paris MM, Ramilo O, McCracken GH Jr. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1995;39:2171-5.
45. Ward JI, Moellering RC Jr. Susceptibility of pneumococci to 14 beta-lactam agents: comparison of resistant, intermediate-resistant, and susceptible strains to penicillin. Antimicrob Agents Chemother 1981;20:204-7.
46. Munford RS, Murphy TV. Antimicrobial resistance in Streptococcus pneumoniae: can immunization prevent its spread? J Invest Med 1994;42: 613-21.
47. Moellering RC Jr. Antimicrobial susceptibility of enterococci: in vitro studies of the action of antibiotics alone and in combination. In: Bisno AL, ed. Treatment of infective endocarditis. New York: Grune & Stratton, 1981;81-96.
48. Fantin B, Leclercq R, Arthur M, Duval J, Carbon C. Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium. Antimicrob Agents Chemother 1991;35:1570-5.
49. Hayden MK, Trenholme GM, Schultz JE, Sahm DF. In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. J Infect Dis 1993;167:1224-7
50. Bingen E, Lambert-Zechovsky N, Leclercq R, Doit C, Mariani-Kurkdjian P. Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1990;26:619-26.
51. Fraimow HS, Venuti E. Inconsistent bactericidal activity of triple-combination therapy with vancomycin, ampicillin, and gentamicin against vancomycin-resistant, highly ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1992;36:1563-6.
52. Caron F, Pestcl M, Kitzis M-D, Lemeland JF, Humbert G, Gutmann L. Comparison of different β-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly β-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis 1995;171:106-12.
53. Norris AH, Reilly JP, Edelstein PH, Brennan PJ, Schuster MG. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995;20:1137-44.
54. Ünal S, Flokowitsch J, Mullen DL, Preston DA, Nicas TI. In-vitro synergy and mechanism of interaction between vancomycin and ciprofloxacin against enterococcal isolates. J Antimicrob Chemother 1993;31:711-23.
55. O'Donovan CA, Fan-Havard P, Tecson-Tumang FT, Smith SM, Eng RH. Enteric eradication of vancomycin-resistant Enterococcus faecium with oral bacitracin. Diagn Microbiol Infect Dis 1994;18:105-9.
56. Montecalvo MA, Horowitz H, Carbonaro C, Seiter K, Wormser GP. Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin and ampicillin-resistant Enterococcus faecium (VAREF). In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Fla., October 4-7,1994. Washington, D.C.: American Society for Microbiology, 1994:145. abstract.
57. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 1995;44(RR-12):1-13.
58. Tenover FC, Swenson JM, O'Hara CM, Stocker SA. Ability of commercial and reference antimicrobial susceptibility testing methods to detect vancomycin resistance in enterococci. J Clin Microbiol 1995;33:1524-7.
59. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992;15:77-83.
60. Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978;299:735-40.
61. Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40:1208-13.
62. Thornsberry C, Brown SD, Yee YC, et al. Increasing penicillin resistance in Streptococcus pneumoniae in the U.S. Infect Med 1993;Suppl/December:15-24.
63. Laible G, Spratt BG, Hakenbeck R. Interspecies recombinational events during the evolution of altered PBP 2x genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Mol Microbiol 1991;5:1993-2002.
64. Coffey TJ, Dowson CG, Daniels M, Spratt BG. Horizontal spread of an altered penicillin-binding protein 2B gene between Streptococcus pneumoniae and Streptococcus oralis. FEMS Microbiol Lett 1993;110:335-40.
65. Figuciredo AM, Connor JD, Severin A, Vaz Pato MV, Tomasz A. A pneumococcal clinical isolate with high-level resistance to cefotaxime and ceftriaxone. Antimicrob Agents Chemother 1992;36:886-9.
66. Thacker SB, Addiss DG, Goodman RA, Holloway BR, Spencer HC. Infectious diseases and injuries in child day care: opportunities for healthier children. JAMA 1992;268:1720-6.
67. Reves RR, Jones JA. Antibiotic use and resistance: patterns in day care centers. Semin Pediatr Infect Dis 1990;1:212-21.
68. Munoz R, Musser JM, Crain M, et al. Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin binding protein profile, surface protein A typing, and multilocus enzyme analysis. Clin Infect Dis 1992;15:112-8.
69. Finland M. Recent advances in the epidemiology of pneumococcal infections. Medicine (Baltimore) 1942;21:307-44.
70. Tomasz A. Multiple-antibiotic-resistant pathogenic bacteria: a report on the Rockefeller University Workshop. N Engl J Med 1994;330:1247-51.
71. Kanra GY, Ozen H, Secmeer G, Ceyhan M, Ecevit Z, Belgin E. Beneficial effects of dexamethasone in children with pneumococcal meningitis. Pediatr Infect Dis J 1995;14:490-4.
72. Paris MM, Hickey SM, Uscher MI, Shelton S, Olsen KD, McCracken GH Jr. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1994;38:1320-4.
73. Friedland IR, Paris M, Ehrett S, Hickey S, Olsen K, McCracken GH Jr. Evaluation of antimicrobial regiment for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993;37:1630-6.
74. Jorgensen JH, Ferraro MJ, McElmeel ML, Spargo J, Swenson JM, Tenover FC. Detection of penicillin and extended-spectrum cephalosporin resistance among Streptococcus pneumoniae clinical isolates by use of the E test. J Clin Microbiol 1994;32:159-63.
75. Performance standards for antimicrobial susceptibility testing. Sixth informational supplement M100-S6. Vol. 15. No. 14. Villanova, Pa.: National Committee for Clinical Laboratory Standards, 1995.
76. Moellering RC Jr. Emergence of Enterococcus as a significant pathogen. Clin Infect Dis 1992;14:1173-6.
77. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991;91:Suppl 3B:3B-72S-3B-75S.
78. Moellering RC Jr, Krogstad DJ. Antibiotic resistance in enterococci. In: Schlessinger D, ed. Microbiology - 1979. Washington, D.C.: American Society for Microbiology, 1979:293-8.
79. Clewell DB. Movable genetic elements and antibiotic resistance in enterococci. Eur J Clin Microbiol Infect Dis 1990;9:90-102.
80. Krogstad DJ, Pargwette AR. Defective killing of enterococci: a common property of antimicrobial agents acting on the cell wall. Antimicrob Agents Chemother 1980;17:965-8.
81. Zervos MJ, Kauffman CA, Therasse PM, Bergman AG, Mikesell TS, Schaberg DR. Nosocomial infection by gentamicin-resistant Streptacoccus faecalis: an epidemiologic study. Ann Intern Med 1987;106:687-91.
82. Grayson ML, Eliopoulos GM, Wennersten CB, et al. Increasing resistance to β-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother 1991; 35:2180-4.
83. Ingerman MJ, Santoro J. Vancomycin: a new old agent. Infect Dis Clin North Am 1989;3:641-51.
84. Ena J, Dick RW, Jones RN, Wenzel RP. The epidemiology of intravenous vancomycin usage in a university hospital. JAMA 1993;269:598-602.
85. Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin-resistant enteroeocci. Lancet 1988;1:57-8.
86. Gaynes R, Edwards J, National Nosocomial Infection Surveillance (NNIS) System. Nosocomial vancomycin resistant enteroeocci (VRE) in the United States, 1989-1995: the first 1000 isolates. Infect Control Hosp Epidemiol 1996;17:Suppl:P18. abstract.
87. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:993-1000.
88. Livornese LL Jr, Dias S, Samel C, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992;117:112-6.
89. Boyle JF, Soumakis SA, Rendo A, et al. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 1993;31:1280-5.
90. Handwerger S, Raucher B, Altarac D, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993;16:750-5.
91. Boyce IM, Opal SM, Chow JW, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994;32:1148-53.
92. Sader HS, Pfaller MA, Tenover EC, Hollis RJ, Jones RN. Evaluation and characterization of multiresistant Enterococcus faecium from 12 U.S. medical centers. J Clin Microbiol 1994;32:2840-2.
93. Bates J, Jordens JZ, Griffiths DT. Farm animals as a putative reservoir for vancomycin-resistant enterococcal infection in man. J Antimicrob Chemother 1994;34:507-14.
94. Klare I, Heier H, Claus H, Reissbrodt R, Witte W. vanA-mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry. FEMS Microbiol Lett 1995;125:165-71. [Erratum, FEMS Microbiol Lett 1995;127:273.]
95. Leclercq R, Derlot E, Weber M, Duval J, Courvalin P. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1989;33:10-5.
96. Noble WC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;93:195-8.
97. Shlaes DM, Etter L, Gutmann L. Synergistic killing of vancomycin-resistant enteroeocci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin. Antimicrob Agents Chemother 1991;35:776-9.
98. Walsh CT. Vancomycin resistance: decoding the molecular logic. Science 1993;261:308-9. [Erratum, Science 1993;262:164.]
99. Billot-Klein D, Gutmann L, Sablé S, Guittet E, van Heijenoort J. Modification of peptidoglycan precursors is a common feature of the low-level vancomycin-resistant VANB-type Enterococcus D366 and of the naturally glycopeptide-resistant species Lactobacillus casei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Enterococcus gallinarum. J Bacteriol 1994;176:2398-405.
100. Quintiliani R Jr, Evers S, Courvalin P. The vanB gene confers various levels of self-transferable resistance to vancomycin in enteroeocci. J Infect Dis 1993;167:1220-3.
101. Dutka-Malen S, Leclercq R, Coutant V, Duval J, Courvalin P. Phenotypic and genotypic heterogencity of glycopeptide resistance determinants in gram-positive bacteria. Antimicrob Agents Chemother 1990;34:1875-9.
102. Performance standards for antimicrobial disk susceptibility tests: approved standard. 5th ed. Vol. 13. No. 24. Villanova, Pa.: National Committee for Clinical Laboratory Standards, 1993. (NCCLS document no. M2-A5.)
103. Willey BM, Kreiswirth BN, Simor AE, et al. Identification and characterization of multiple species of vancomycin-resistant enrerococci, including an evaluation of Vitek software version 7.1. J Clin Microbiol 1993;31:2777-9.
104. Swenson JM, Clark NC, Ferraro MJ, et al. Development of a standardized screening method for detection of vancomycin-resistant enterococci. J Clin Microbiol 1994;32:1700-4.